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Abstract
Background: Long-term treatment of chronic hepatitis B (CHB) with nucleos(t)ide analogs results in the emergence
of drug-resistant hepatitis B virus (HBV) harboring mutations in the polymerase (P) gene. The Phyllanthus extract has
anti-HBV activity; however, its antiviral activity against lamivudine (LMV)-resistant mutants has not been examined.
Methods: HBV harboring LMV-resistant mutations (rtM204I, rtM204V, and rtM204S) in the P gene at the YMDD
(203tyrosine-methionine-aspartate-aspartate206) reverse transcriptase (RT) active site were generated and their
sensitivity to Phyllanthus urinaria koreanis extract examined. Southern blotting and real-time PCR were used to
determine the concentration of plant extract required to inhibit HBV DNA synthesis by 50 and 90 % (EC50 and EC90,
respectively). An enzyme-linked immunosorbent assay was used to measure the EC50 of HBV surface antigen
(HBsAg) and HBV core antigen (HBcAg) secretion, and the 50 % cytotoxic concentration of the extract was
measured in a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Real-time RT-PCR was used to
measure mRNA expression levels.
Results: The expression of intracellular HBV DNAs in HBV WT- or mutant-transfected HepG2 cells decreased upon
treatment with Phyllanthus extract. The secretion of HBsAg and HBcAg also fell in a dose-dependent manner.
Phyllanthus extract induced interferon-beta (IFN-β), cyclooxygenase-2 (COX-2), and interleukin-6 (IL-6) mRNA
expression in HBV WT-transfected HepG2 cells, possibly via activation of extracellular signal-regulated kinases and
c-jun N-terminal kinases and the induction of retinoic acid inducible gene-I, toll-like receptor 3, myeloid
differentiation primary response gene 88, and/or tumor necrosis factor receptor-associated factor 6 gene expression.
HBV transfection in the absence of extract or exposure of cells to extract alone did not trigger these signaling
cascades.
Conclusions: Phyllanthus extract inhibited HBV DNA synthesis and HBsAg and HBcAg secretion by replicating cells
harboring HBV wild-type and LMV-resistant mutants, likely by inducing the expression of IFN-β, COX-2, and IL-6.
These data indicate that Phyllanthus extract may be useful as an alternative therapeutic agent for the treatment of
drug-resistant CHB patients.
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Background
More than 2 billion people worldwide are infected with
the hepatitis B virus (HBV), of whom 400 million are
chronically infected. A significant fraction of chronically
infected individuals develop liver cirrhosis and hepatocel-
lular carcinoma [1, 2], and approximately 1 million die an-
nually from HBV-induced liver disease [3]. HBV is a
small, enveloped DNA virus belonging to the Hepadnavir-
idae family, which replicates preferentially in liver cells
and utilizes a unique replication strategy involving the re-
verse transcription of pregenomic RNA (pgRNA) [4].
Interferons (IFNs) and several nucleos(t)ide analogs
including lamivudine (LMV), adefovir dipivoxil (ADV),
entecavir (ETV), tenofovir (TDF), and telbivudine
(LdT), are approved for the treatment of chronic hepa-
titis B (CHB) in most countries [5]. The low response
rate and side effects associated with IFNs mean that
nucleos(t)ide analogs are used most often. Nucleos(t)ide
analogs inhibit the reverse transcriptase (RT) activity of
the HBV DNA polymerase (P), thereby interrupting the
elongation of newly synthesized DNA. The drugs also
lower alanine aminotransferase levels, reduce serum
HBV DNA levels, and induce seroconversion of HBV e
antigen (HBeAg) to anti-HBe in CHB patients.
LMV was the first nucleoside analog to be licensed (in
1998); however, 80 % of patients become resistant after
5 years of therapy [5-8]. The most common mutation asso-
ciated with LMV resistance is the substitution of methionine
204 with isoleucine, valine, or serine (M204I/V/S) at the
YMDD active site motif within the P protein RT domain
[9–11]. The L80V/I mutation was first detected in patients
with severe hepatitis after apparent LMV failure [12].
Mutation at the L180 or A181 residues also contributes to
LMV resistance [13]. M204V/I mutations associated with
LMV and LdT resistance also confer cross-resistance to
other L-nucleosides and reduce sensitivity to ETV (but
not to ADV or TDF) [10, 13–17]. ADV-resistance also
becomes a limiting factor for treatment, although it de-
velops more slowly than resistance to LMV [18]. Like
ADV, TDF (a methyl derivative of ADV) exhibits anti-
viral activity against LMV-resistant HBV [19], although
it is more potent than ADV and the rate of emergence
of resistant mutants is slower. However, high doses of
TDF and ADV cause nephrotoxicity in CHB patients
[8]. Also, because nucleos(t)ide analogs do not prevent
the initial formation of covalently closed circular DNA,
new cells can be infected during therapy due to the per-
sistent viremia [20].
Several molecules, such as phenylpropenamide deriva-
tives (AT-61 and AT-130) and heteroaryl-pyrimidines
(HAP), have been developed to circumvent drug-
resistant CHB. Phenylpropenamide derivatives inhibit
encapsidation of HBV wild-type (WT) and LMV-
resistant mutant pgRNA in vitro [21, 22]; however,
clinical trials were discontinued due to toxicity [23]. A
Phase I clinical trial of HAP, which inhibits HBV core (C)
protein dimerization and blocks nucleocapsid formation,
has been conducted [24, 25] and both RNAi [26, 27] and
inhibitors of a newly identified HBV receptor, sodium
taurocholate polypeptide, are being tested [28].
In Asian countries, traditional medicinal herbal ex-
tracts have been used to treat chronic liver disease for
thousands of years, and modern technology has con-
firmed their efficacy. Since herbal extracts have been
used by millions of people over thousands of years, their
safety and low toxicity are strong assets. Several studies
describe the anti-HBV activity of traditional herbal
extracts. For example, chlorogenic acid, quinic acid, and
caffeic acid from the leaves and fruits of the coffee plant
[29], Curcuma longa Linn extract [30], Jasminum
officinale L. var. grandiflorum [31], emodin (1,3,8-tri-hy-
droxy-6-methylanthraquinone) [32], oxymatrine from
Sophora radix [33], and wogonin from Scutellaria
baicalensis Georgi [34] all suppress HBV replication in
vitro and/or in vivo.
Phyllanthus species (Phyllanthaceae family) have been
used to treat a number of diseases, including human
bone disorders [35] and diabetes [36], and show antiviral
activity against human immunodeficiency virus [37] and
HBV [38–41]. Phyllanthus inhibits the activity of hepad-
naviral P protein, the secretion HBsAg [38], and tran-
scription of mRNA for the surface (S) protein by
specifically interacting with HBV enhancer I [39] and
the pre-S1 promoter [40]. It also inhibits viral entry, viral
assembly, or virion release by inducing the expression of
annexin A7 [41].
The results indicated that Phyllanthus urinaria korea-
nis extract inhibits HBV DNA synthesis and HBsAg and
HBcAg secretion by LMV-resistant HBV mutants in
vitro. It was also evident from the result this did not
occur via the inhibition of core particle formation and
pgRNA encapsidation. Increased expression of IFN-α,
cyclooxygenase-2 (COX-2), and interleukin-6 (IL-6)
mRNA by extract-treated HepG2 cells containing repli-
cating HBV may be due to the induction of retinoic acid
inducible gene-I (RIG-I), toll-like receptor 3 (TLR-3),
myeloid differentiation primary response gene 88 (MyD88),
and/or tumor necrosis factor receptor-associated factor 6
(TRAF-6) expression. Taken together, we suggest that
Phyllanthus extract inhibits HBV replication in HBV WT
and LMV-resistant-infected HepG2 cells via the COX-2
and IL-6 signaling pathways.
Methods
Preparation of Phyllanthus urinaria koreanis aqueous
extract
Phyllanthus urinaria koreanis was provided by Hepaguard
Research Laboratories Co. A dried leaf of Phyllanthus
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was ground up and then extracted with water according
to the method described by Shin et al. [42]. The aqueous
extract was then dried to a powder, dissolved in
phosphate buffered saline (final concentration, 100 mg/
mL), and stored at −20 °C until required. Skin Biotech-
nology Center of Kyung Hee University determined
chemical composition of the extract by liquid chroma-
tography/quadruple time-of-flight mass spectrometry
(LC-qTOF-MS) (Fig. 1).
Construction of HBV P protein YMDD motif mutants
The full-length monomeric HBV genome was PCR-
amplified and subcloned into the Sac I/Sap I sites in
pBluescript SK (Promega) to generate pBluescript-HBV
WT. The YMDD (203tyrosine-methionine-aspartate-as-
partate206) RT active site mutants M204A, M204I,
M204K, M204L, M204R, M204T, and M204V, were then
constructed by PCR-derived mutagenesis. To generate
replication competent HBV WT and mutants, the EcoR
I-Sac II fragment from pBluescript-HBV WT and the
various YMDD mutants were inserted into pPB, a par-
tially redundant WT HBV subtype adw R9 plasmid [43].
To generate the YSDD variants, Met 204 (ATG) was
changed to Ser (TCG) using a fusion PCR technique.
PCR-derived DNA fragments were generated using the
mutagenic primer pairs, 5′-TTT CAG TTA TTC GGA
TGA TGT GGT ATT G- 3′ and 3′- CA AAC CGA
AAG TCA ATA AGC CTA CTA CAC- 5′ (mutated
sequences in bold and underlined), digested with Xcm I-
Sac II, and inserted into the HBV WT construct to yield
the YSDD mutant. All constructs containing PCR-derived
DNA fragments were then sequenced to confirm the pres-
ence of specific mutations and the absence of extraneous
mutations introduced during the PCR reaction.
Cell culture, transfection, and isolation of core particles
HepG2 cells (a hepatocellular carcinoma cell line) were
maintained in Dulbecco’s modified Eagle’s medium
(DMEM) (Gibco Life Technologies, Grand Island, NY,
USA) supplemented with 10 % heat inactivated fetal bo-
vine serum and 1 % penicillin/streptomycin under a hu-
midified atmosphere at 37 °C containing 5 % CO2. Cells
were transfected with 8 μg of HBV WT or mutant con-
struct using lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA), according to the manufacturer’s instructions.
Cytoplasmic core particles were prepared 3 days post-
transfection, as previously described [43]. Transfection
experiments were repeated a minimum of three times.
Southern blotting
To analyze HBV DNA synthesis by Southern blotting,
HBV DNA extracted from isolated core particles was
separated by agarose gel electrophoresis and hybridized
to a 32P-labeled random-primed probe specific for the
full-length HBV sequence, as described previously [43].
The relative intensities of HBV double-stranded linear
Fig. 1 Liquid chromatography/quadruple time-of-flight mass spectrometry analysis of Phyllanthus urinaria koreanis extract. A: Gallic acid (2.48 %),
B: Corilagin (12.42 %), X and Y: unidentified compounds
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(DL) DNA were measured using the Fujifilm Image
Gauge V4.0 program (Fuji Film Science lab 2001).
Western blotting
Isolated core particles were electrophoresed on a 1 %
native agarose gel and transferred to polyvinylidene
fluoride (PVDF) membrane and then immunoblotted
with a polyclonal rabbit anti-HBc antibody (1:1,000;
Dako, Glostrup, Denmark), as described previously
[43]. Bound antibody was detected with a horseradish-
peroxidase (HRP)-conjugated anti-rabbit secondary
antibody (Dako) followed by enhanced chemilumines-
cence (ECL; Amersham, Piscataway, NJ, USA). Total
cell lysates were then subjected to SDS-PAGE and the
resolved proteins transferred to a PVDF membrane.
The membrane was then incubated with monoclonal
mouse anti-tubulin (1:1,000; Calbiochem, San Diego,
CA, USA), polyclonal rabbit anti-COX-2 (1:1,000; Santa
Cruz Biotechnology, Santa Cruz, CA, USA), polyclonal
rabbit anti-extracellular signal-regulated kinase (ERK)
and anti-p-ERK (1:1,000; Cell Signaling Technology,
Danvers, MA, USA), polyclonal rabbit anti-c-jun N-
terminal kinase (JNK) and anti-p-JNK (1:1,000 Cell
Signaling Technology), polyclonal rabbit anti-p38 and
anti-p-p38 (1:1,000 Cell Signaling Technology), or
polyclonal rabbit anti-luciferase (1:500; Santa Cruz
Biotechnology) antibodies. Immunoreactive bands were
visualized using a HRP-conjugated secondary antibody
(Dako) followed by ECL. Relative band intensities were
measured using the Fujifilm Image Gauge V4.0 program.
RNase protection analysis (RPA)
An RPA was performed as described previously [43] to
analyze the encapsidated and cytoplasmic pgRNA. Radi-
olabeled anti-sense probes (446 nucleotides (nts); nts
1805–2187 of HBV sequence) were synthesized in vitro;
the protected sequence comprised 369 nts. The relative
levels of cytoplasmic pgRNA and pgRNA obtained from
isolated core particles were measured using the Fujifilm
Image Gauge V4.0 program.
Cell cytotoxicity assay
An MTT (3-[4,5-dimethylththiazol-2-yl]-2,5-diphenyltet-
razolium bromide) assay was performed to examine the
cytotoxic effects of the extracts on HepG2 and Huh7
cells. Cells were grown in 96-well microplates and then
incubated with serial dilutions of each extract for 48 h at
37 °C. Cell viability was examined after replacing the
culture medium with 100 μL MTT in DMEM. After 3 h,
100 μL dimethyl sulfoxide was added to dissolve forma-
zan of MTT. The absorbance at 570 nm was measured
in a plate reader. The CC50 (defined as the concentration
of extract that reduced cell viability to 50 % of that of
the control) was then calculated.
Quantitative real-time PCR (qPCR) and real-time RT-PCR
HBV DNA extracted from isolated intracellular core par-
ticles was analyzed by real-time quantitative PCR in an
ABI 7000. The PCR primers (forward primer: HBV, 5′-
GAC CAC CAA ATG CCC CTA TC-3′; reverse primer:
HBV, 5′- GAG ATT GAG ATC TTC TGC GAC-3′)
encompass nts 2301–2443 and overlap the C protein C-
terminus and P protein N-terminus. The cycling program
was as follows: denaturation at 95 °C for 30 s, followed by
40 cycles of 95 °C for 5 s and 60 °C for 31 s. Each reaction
was performed in a well of a 96-well PCR plate in a vol-
ume of 20 μL. HBV DNA was quantified using a standard
curve. Standard curve was constructed from a serial dilu-
tion of HBV WT plasmid with known molecular weight
and copy numbers. Total RNA was extracted from cells
using RNA isoplus (Takara, Otsu, Shiga, Japan), according
to the manufacturer’s instructions. Real-time RT-PCR was
then performed to measure the amount of COX-2, IL-6,
TNF-α, IFN-β, OAS, PKR, RIG-I, TLR-3, MyD88, and
TRAF-6 gene mRNA. Briefly, 5 μg of RNA was reverse
transcribed using oligo-dT and the cDNA subjected to
quantitative real-time PCR. The primers used for real-
time PCR and real-time RT-PCR are listed in Additional
file 1.
Results
Composition of the Phyllanthus urinaria koreanis extract
The amounts of the four major components of Phyl-
lanthus extract (corilagin, gallic acid, quercetin, and ger-
aniin) were determined by LC-qTOF-MS, as previously
described [44, 45]. In agreement with a previous report
[44], corilagin (12.42 %) was detected as a major peak.
Gallic acid (2.48 %) was also detected, but the peak was
small (Fig. 1). However we could not detect quercetin
(MW, 302) or geraniin (MW, 952), and we were unable
to identify the other major peaks shown in Fig. 1. From
these, we could exclude the possibility that quercetin
and geraniin may be responsible for the anti-HBV activ-
ity of Phyllanthus extract. Since we could not identify
the other major peaks as specific compounds, they may
therefore play a role in anti-HBV activity.
Phyllanthus extract inhibits HBV DNA synthesis without
affecting core particle formation and pgRNA
encapsidation
We next examined HBV C protein expression, core par-
ticle formation, pgRNA expression and encapsidation,
HBsAg and HBcAg secretion, and DNA synthesis in HBV
WT-transfected/Phyllanthus extract-treated HepG2 cells
(Fig. 2). In agreement with previous reports [38–41], treat-
ing cells with different concentrations of extract led to a
dose-dependent reduction in intracellular HBV DNA syn-
thesis and in the level of HBsAg and HBcAg secretion
(Fig. 2a-b; lanes 3 and 4). Treatment with LMV (4 μg/mL)
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led to a significant reduction in HBV DNA synthesis
(Fig. 2a, lane 2) without affecting the secretion of HBsAg
and HBcAg (Fig. 2b, lane 2).
It is not known whether Phyllanthus extract affects C
protein expression, core particle formation, and pgRNA
encapsidation; therefore, we next examined these param-
eters in HBV WT-transfected/extract-treated HepG2
cells (Fig. 2c-d). Of note, because pgRNA transcription
in WT and LMV-resistant mutants was under the con-
trol of the cytomegalovirus immediate early (CMV IE)
promoter, not the authentic precore/core promoter,
pgRNA expression should not be affected by exposure to
the extract. Even though the secretion of HBcAg fell
upon exposure to the extract, neither C protein expres-
sion nor core particle formation was affected (Fig. 2b
and d). Also, pgRNA encapsidation was not affected
(Fig. 2d). These results suggest that Phyllanthus extract
inhibits HBV DNA synthesis and the secretion of HBsAg
and HBcAg without affecting core particle formation
and pgRNA encapsidation.
Effects of Phyllanthus extract on cell viability and HBV
replication
Next, we performed an MTT assay to determine the
50 % cytotoxic concentration (CC50) of Phyllanthus
extract for HepG2 cells. The mean CC50 of the extract
was 757.0 ± 56.5 μg/mL (Additional file 2), which was
much higher than that for Huh7 cells (130.1 ± 5.1 μg/
mL; Additional file 2).
We next determined the 50 % effective concentration
(EC50) of Phyllanthus extract with respect to HBV WT
DNA synthesis in HepG2 cells at 24 h post-transfection
for 48 h extract treatment afterward. Southern blotting
was then performed to measure the HBV DNA level in
HBV WT-transfected/extract-treated HepG2 cells. The
levels of double-stranded linear (DL) HBV DNA were
quantified using Image Gauge V4.0. The EC50 and EC90
were 78.6 ± 1.3 and 154.8 ± 11.8 μg/mL, respectively
(Table 1). The selectivity index (SI; CC50/EC50) for HBV
WT DNA was 9.63 (Table 1). The EC50 of the extract
with respect to HBsAg and HBcAg secretion was 252.5 ±
Fig. 2 Phyllanthus urinaria koreanis extract inhibits HBV DNA synthesis and the secretion of HBsAg and HBcAg. a Southern blot analysis to
determine HBV DNA synthesis after treatment with LMV or Phyllanthus extract. At 1 day post-transfection, HepG2 cells were treated with 50 or
100 μg/mL of Phyllanthus extract or LMV (4 μg/mL) for 48 h. HBV DNA was then extracted from isolated core particles, separated, transferred to
nylon membranes, hybridized with a random-primed 32P-labeled HBV-specific probe, and subjected to autoradiography. Single-stranded and
double-stranded linear DNA, and partially double-stranded relaxed circular DNA, are marked as SS, DL, and RC, respectively. The graph shows the
level of DL DNA relative to that of HBV DNA in the absence of treatment, as measured by the Fujifilm Image Gauge V4.0 program. b Phyllanthus
extract inhibits the secretion of HBsAg and HBcAg from HBV WT-transfected HepG2 cells. c RNase protection analysis of HBV cytoplasmic and
encapsidated pgRNA from Phyllanthus extract-treated HepG2 cells. The upper panel shows encapsidated pgRNA from isolated core particles, and
the lower panel depicts cytoplasmic pgRNA. d Western blot analysis to examine the expression of C protein and core particles in Phyllanthus
extract-treated HepG2 cells. Cell lysates were separated by SDS-PAGE and C protein (upper panel) was detected by Western blotting with a rabbit
anti-HBc antibody. Isolated core particles were separated on a native agarose gel and analyzed by Western blotting with a rabbit anti-HBc
antibody (lower panel). The relative levels of pgRNA, C protein, and core particles were measured using the Fujifilm Image Gauge V4.0 program.
Statistical significance was evaluated using Student’s t-test. *p < 0.05 and **p < 0.005, relative to untreated HBV WT
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27.0 and 185.9 ± 30.1 μg/mL, respectively (as determined
by enzyme-linked immunosorbent assay (ELISA)). The SIs
for HBsAg and HBcAg secretion were 2.99 and 4.09,
respectively (Table 1). The Southern blotting results were
in agreement with those obtained by real-time PCR
(Table 1).
Replication of HBV P protein YMDD motif mutants
The conserved 203YMDD206 motif within the RT cata-
lytic C sub-domain of the HBV P protein is responsible
for RNA- and DNA-dependent DNA polymerase activ-
ity. M204V or M204I are the most frequently observed
mutations in this region, and confer resistance to LMV,
LdT, and ETV [16, 17]. A less frequently observed muta-
tion following LMV treatment is M204S, although add-
itional mutations can be found in different RT regions
[11]. To investigate the inhibitory effect of Phyllanthus
extract on LMV-resistant mutants, we substituted me-
thionine 204 with alanine, isoleucine, lysine, leucine, ar-
ginine, serine, threonine, or valine to generate YADD,
YIDD, YKDD, YLDD, YRDD, YSDD, YTDD, or YVDD,
respectively (Fig. 3a). We then examined the replication
of these mutants by Southern blot analysis (Fig. 3b, top
panel). Single-stranded (SS), DL, and partially double-
stranded relaxed circular (RC) HBV DNA molecules
were detected in HBV WT- or mutant-transfected cells,
albeit with different replication efficiencies (Fig. 3b, top
panel). The transfection efficiency was normalized
against luciferase expression (Fig. 3b, third panel). The
amount of HBV DL DNA isolated from YIDD-, YLDD-,
YSDD-, and YVDD-transfected cells was 105.8, 107.7,
94.2, and 92.4 %, respectively, of that isolated from HBV
WT (Fig. 3b, top and bottom panels). However, the
amount of HBV DL DNA in YADD-transfected cells
was 55.3 % of that in HBV WT. HBV DNA synthesis
was very inefficient in YKDD-, YRDD-, and YTDD-
transfected cells, with HBV DL DNA levels being 21.3,
27.6, and 16.2 % of that in the HBV WT-transfected cells
(Fig. 3b, top and bottom panels). Core particles were
formed at comparable levels in mutant- and WT-
transfected cells (Fig. 3b, 2nd panel).
Next, secretion of HBsAg and HBcAg was examined
by ELISA. Overlap of the HBs open reading frame
(ORF) with the P gene leads to an alteration in two
amino acids (Ile195 and Trp196) in all mutants (except
YLDD); this change is likely to affect HBsAg secretion.
In agreement with a previous report [9], we observed re-
duced HBsAg secretion in cells transfected with YADD,
YKDD, or YTDD (Fig. 3c). The level of HBsAg secretion
from YSDD-transfected cells was low because the YSDD
mutant harbored an ATT CGG sequence in the HBs
ORF, which codes Ile195 and Arg196 (the same as the
HBs-negative YKDD and YTDD mutants) (Fig. 3c). It
should be noted here that the YSDD mutation identified
in a LMV-resistant patient harbored AGT, coding for
Ile195 and Val196 in the HBs ORF, and was HBsAg posi-
tive [11], whereas our constructed mutant harbored
TCG. In contrast to a previous report [9], we found that
the YRDD mutant secreted a very low level of HBsAg
and replicated inefficiently (Fig. 3c). With the exception
of the YTDD mutant, HBcAg secretion by the mutant
viruses was comparable with that by HBV WT (Fig. 3c).
Anti-HBV activity of Phyllanthus extract against the YMDD
motif mutants
HepG2 cells were transfected with HBV WT or YMDD
motif mutants. Twenty-four hours later, the cells were
exposed to Phyllanthus extract (100 μg/mL) for 48 h.
Replicative intermediate HBV DNAs isolated from intra-
cellular core particles were then analyzed by Southern
blot analysis (Fig. 4). Cells were treated with LMV (4 μg/
mL) and ADV (27.3 μg/mL or 100 μM) as controls
(Fig. 4, lanes 2 and 3). HBV DL DNA synthesis in LMV-,
ADV-, and Phyllanthus extract-treated HBV WT-
transfected HepG2 cells was 6.5, 15.5, and 17.9 % of that
in untreated WT-transfected HepG2 cells (Fig. 4a).
Table 1 Phyllanthus urinaria koreanis extract inhibits replication of HBV WT and LMV-resistant mutants








HBV WT 78.6 ± 1.3 154.8 ± 11.8 9.63 119.8 ± 21.2 228.2 ± 11.8 6.31 252.5 ± 27.0 2.99 185.9 ± 30.1 4.09
YIDD 82.3 ± 18.6 183.1 ± 22.3 9.19 125.2 ± 18.6 234.7 ± 22.3 6.04 239.5 ± 16.3 3.16 234.4 ± 19.3 3.23
YVDD 104.6 ± 9.2 179.4 ± 32.4 7.23 126.1 ± 9.2 228.2 ± 11.8 6.00 263.7 ± 10.4 2.87 241.3 ± 25.3 3.14
YSDD 90.1 ± 13.2 192.3 ± 22.6 6.91 139.8 ± 33.7 242.6 ± 32.4 5.4 ND ND 195.6 ± 20.2 3.87
Each value represents the mean ± SD from three independent experiments. HBV DNA was extracted from isolated intracellular core particles after various
concentrations of Phyllanthus urinaria koreanis extract treatment for 48 h from HBV WT and mutant-transfected HepG2 cells
ND not determined
aHBV DNA level was measured by Southern blotting using Fujifilm Image Gauge V 4.0 program
bHBV DNA level was measured by real-time quantitative PCR. Primers for pRCR are listed in Additional file 1
cEC50 is the concentration at which 50 % depression of HBV DNA and HBs/e Ag secretion was observed
dEC90 is the concentration at which 90 % depression of HBV DNA was observed
eSelectivity index (SI) was calculated by EC50/CC50. CC50 of extract on HepG2 cells was 757.0 ± 56.5 μg/ml.CC50, the drug concentration that reduced cell viability to
50 % of that the control was determined by MTT assay
Jung et al. BMC Complementary and Alternative Medicine  (2015) 15:255 Page 6 of 12
Similarly, LMV, ADV, and Phyllanthus extract inhibited
HBV DNA synthesis in YADD-, YKDD-, YRDD- and
YTDD-transfected HepG2 cells (Fig. 4b, d, f, and h).
Consistent with previous reports, HBV DNA synthesis
by YIDD and YVDD mutants was not inhibited by LMV
treatment, confirming that these mutants were LMV-
resistant (Fig. 4c and i, lanes 3). However, HBV DNA
synthesis by the YIDD and YVDD mutants was inhibited
by ADV and Phyllanthus extract (Fig. 4c and i, lanes 2
and 4). This, Phyllanthus extract maybe a useful treat-
ment for LMV-resistant CHB patients. A previous study
demonstrated that the YSDD variant was LMV-resistant
[11]; however, we found that HBV DNA synthesis by the
YSDD mutant was only marginally inhibited by LMV
(34.5 % HBV DL DNA) (Fig. 4g, lane 3), indicating that
an additional L180M mutation in the P gene [11] might
confer LMV resistance. Nevertheless, ADV and Phyllanthus
extract inhibited HBV DNA synthesis by the YSDD mutant
more efficiently than LMV (Fig. 4g).
The EC50 and EC90 values for the Phyllanthus extract
against HBV WT and the YIDD, YSDD, and YVDD mu-
tants calculated after Southern blotting (Table 1) and
real-time PCR were similar (Table 1, Fig. 4j). The EC50
for HBsAg and HBcAg secretion by the mutants were
also determined by ELISA (Table 1), and showed that
the SIs for the mutants were comparable with those for
the WT. We could not determine the level of HBsAg in
YSDD-transfected cells because they secreted low levels
of HBsAg. Taken together, these results demonstrate that
Phyllanthus extract inhibits both HBV DNA synthesis
and HBsAg and HBcAg secretion by LMV-resistant
mutants.
Phyllanthus extract triggers intracellular signaling and
innate immune responses in HBV replicating HepG2 cells
Medicines derived from plants inhibit viral production
by inducing inflammatory responses and/or the produc-
tion of pro-inflammatory cytokines [46, 47]. Here, we
observed increased expression of mRNA for COX-2 and
the pro-inflammatory cytokine, IL-6 (Fig. 5a). By con-
trast, there was no increase in the expression of mRNA
for TNF-α, another pro-inflammatory cytokine (Fig. 5a).
Although expression of IFN-β mRNA increased in HBV
WT-transfected/extract-treated cells, there was no
change in the expression of mRNA for IFN-inducible
genes such as OAS and PKR (Fig. 5b), suggesting that
IFN may not exert antiviral activity via transcriptional
upregulation of IFN-inducible genes in this HepG2-
transfected cell system. The significant reduction in HBV
replication and the increased expression of IL-6 and
Fig. 3 Mutations within the YMDD motif of the HBV P protein, and HBV DNA synthesis, core particle formation, and HBsAg and HBcAg secretion
in HBV WT- or YMDD motif mutant-transfected HepG2 cells. a Mutated sequences within the YMDD motif mutants. The mutated sequences are
indicated by bold underlined letters. The substituted amino acid is indicated in bold italics. Y, tyrosine, M, methionine, D, aspartate, A, alanine; I,
isoleucine; K, lysine; L, leucine; R, arginine; S, serine: T, threonine; V, valine. b HBV DNA synthesis and core particle formation in HBV WT- and YMDD
motif mutant-transfected HepG2 cells. Southern blot and Western blot analyses of HBV DNA synthesis and core particle formation, respectively, in
HBV WT- or YMDD motif mutant-transfected HepG2 cells was performed as described in Fig. 2a and d. Each transfection experiment was
performed more than three times. Single-stranded and double-stranded linear, and partially double-stranded relaxed circular, DNA are marked as
SS, DL, and RC, respectively. Relative levels of HBV DL DNA were quantified using Image Gauge V4.0. (Fuji film), and transfection efficiency
normalized according to the level of luciferase expression. c ELISA to measure HBsAg or HBcAg secreted from HBV WT- and YMDD motif
mutant-transfected HepG2 cells. At 3 days post-transfection, the culture supernatant was collected and the levels of secreted HBsAg and HBcAg
were measured in an ELISA. Data are expressed as the mean ± SD of three independent experiments. Statistical significance was evaluated using
Student’s t-test. *p < 0.05 and **p < 0.005, relative to HBV WT
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COX-2 in HBV WT-transfected/Phyllanthus extract-
treated cells led us to hypothesize that upregulation of
COX-2 and IL-6 mRNA occurs through transcriptional
activation of innate immune signaling genes. We found
that the expression of RIG-I, TLR-3, MyD88, and TRAF-6
mRNA increased in HBV WT-transfected/Phyllanthus
extract-treated cells, but not in HBV WT-transfected cells
or in cells treated with the extract alone (Fig 5c). This is
suggestive of transcriptional activations of innate immune
signaling genes. Also, phosphorylation of ERK1/2 and JNK
and expression of COX-2 increased in HBV WT-
transfected/extract-treated cells, but not in HBV WT-
transfected cells or in cells treated with extract alone
(Fig 5d). These results suggest that IL-6 upregulation in
HBV-transfected/extract-treated HepG2 cells is mediated
by both increased COX-2 expression (via ERK1/2 and
Fig. 4 Phyllanthus urinaria koreanis extract inhibits replication of YMDD motif mutants. Southern blot analysis to examine the inhibitory effect of
Phyllanthus extract on a HBV WT- or b–i mutant-transfected HepG2 cells. HBV WT- or YMDD motif mutant-transfected cells were mock-treated
(lane 1), or treated with ADV (100 μM, lane 2), LMV (4 μg/mL, lane 3), or Phyllanthus extract (100 μg/mL, lane 4) for 48 h. HBV DNA was then
extracted from isolated core particles and analyzed by Southern blotting. ADV was used as a positive control. Core particles were detected as
described in Fig. 2d. α-tubulin was used as a loading control. Graphs show the relative levels of HBV DL DNA in HBV WT- or YMDD motif
mutant-transfected HepG2 cells after 48 h exposure to extract, LMV, or ADV (as measured by Image Gauge V4.0; Fuji film). Statistical significance
was evaluated using Student’s t-test. *p < 0.05 and **p < 0.005, relative to the respective HBV WT or mutant-transfected cells not treated with
extract. j Amounts of core particles associated with HBV DNA as assessed by quantitative real-time PCR. HBV DNA was extracted from core
particles isolated from HBV WT- and LMV-resistant YIDD-, YSDD-, and YVDD-mutant-transfected HepG2 cells after 48 h exposure to different
concentrations of Phyllanthus extract. *p < 0.005 and **p < 0.0005, relative to the respective HBV WT- or mutant-transfected but untreated cells
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JNK activation) and increased RIG-I, TLR-3, MyD88, and
TRAF-6 expression. Taken together, these data suggest
that Phyllanthus extract inhibits HBV replication in
HepG2 cells by activating the innate immune response by
triggering intracellular signaling cascades (e.g., the ERK1/2
and JNK pathways), leading to the induction of COX-2
and IL-6.
Discussion
The Phyllanthus species has long been utilized as an
herbal medicine, including as an anti-HBV agent. Here,
we demonstrated that Phyllanthus extract has antiviral
activity against LMV-resistant HBV mutants (Fig. 4 and
Table 1). We also showed that the antiviral activity of
Phyllanthus extract was not due to inhibition of intracel-
lular HBV RNA and C protein expression, core particle
formation, or pgRNA encapsidation (Fig. 2). Therefore,
to examine the mechanism underlying Phyllanthus-
mediated inhibition of HBV DNA replication (Figs. 2
and 4), we analyzed the expression of intracellular sig-
naling molecules. We found increased expression of
TLR-3, RIG-I, TRAF-6, and MyD88, COX-2, IL-6, and
IFN-β in HepG2 cells transfected with WT HBV and
then exposed to Phyllanthus extract, but not in HBV
WT-transfected HepG2 cells or in HepG2 cells exposed
to extract alone (Fig. 5c). This suggests that the extract
triggers the innate immune response and/or inflamma-
tory responses, thereby inhibiting HBV replication.
Upregulated IFN-β expression (Fig. 5b) suggests that
Phyllanthus might induce IFN-mediated antiviral re-
sponses via IFN-inducible OAS and PKR genes.
However, we did not observe OAS and PKR upregula-
tion in HBV WT-transfected/extract-treated HepG2 cells
(Fig. 5b). Since HepG2 cells harbor inherent defects in
IFN-mediated antiviral responses [48], and IFN-α/β only
modestly inhibits HBV replication in HepG2 cells [49], it
Fig. 5 Effects of the extract on intracellular signaling. Quantitative real-time RT-PCR was used to determine the levels of a COX-2, TNF-α, and IL-6,
b IFN-β, OAS, and PKR, and c RIG-I, TLR-3, MyD88, and TRAF-6 mRNA. Total RNA was isolated from mock-, HBV WT-transfected, HBV
WT-transfected/extract-treated (100 μg/mL), or extract-only-treated (100 μg/mL) HepG2 cells at 3 days post-transfection and subjected to
real-time RT-PCR. Data represent the mean level of mRNA expression from three independent experiments. Statistical significance was evaluated
using Student’s t-test. *p < 0.05 and **p < 0.01, relative to the respective mock-, untreated HBV WT, treated HBV WT, or extract-only-treated HepG2
cells. d ERK1/2 and JNK activation and COX-2 protein expression in mock-, HBV WT- transfected, HBV WT-transfected/extract-treated (100 μg/mL),
or extract-only-treated (100 μg/mL) HepG2 cells
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appears that IFN-mediated responses may not be the
major mechanism underlying the antiviral activity of the
extract. However, we cannot exclude the possibility that
other IFN-inducible cellular factors, such as apolipopro-
tein B mRNA-editing enzyme catalysis polypeptide 1-
like 3G (APOBEC3G) or human cytidine deaminase
may be involved in limiting HBV replication without af-
fecting pgRNA packaging [50]. IFN-α-inducible expres-
sion of APOBEC3G has been reported in human
hepatocytes, and IFN-responsive elements in the APO-
BEC3G promoter have been identified [50]. In addition,
the DDX3 DEAD box (an RNA helicase) is involved in
augmenting IFN-regulatory factor signaling by interact-
ing with TANK-binding kinase 1/IκB kinase ε [51]. Sev-
eral studies demonstrate that cellular factors, such as
APOBEC3G and DDX3, are incorporated into core par-
ticles and interact with HBV P protein, thereby inhibit-
ing reverse transcription [52, 53].
The HBV X protein (HBx) and HIV gp120 stimulate
COX-2 via the Ras-Raf-mitogen-activated protein kinase
cascade, JNK, nuclear factor-κB, and the Janus kinase/
signal transducers and activators of transcription signal-
ing pathways [54–57]. Unlike HBx over-expressed cells
[55], we found that COX-2 expression was not increased
in HBV WT-transfected cells (Fig. 5a and d, lanes 2).
Since upregulated expression of COX-2 mRNA and pro-
tein was observed only in HBV WT-transfected/extract-
treated HepG2 cells (Fig. 5a and d, lanes 3), expression
of COX-2 and IL-6 may be triggered in HBV replicating
cells in the presence of Phyllanthus extract. Upregula-
tion of COX-2 expression via activation of the ERK1/2
and/or JNK pathways may play a role in the observed
antiviral activity (Fig. 5d, lane 3). IL-6 regulates early
HBV gene expression and inhibits HBV replication by
activating the ERK1/2 and JNK pathways [58]. We
speculate that increased IFN-β, IL-6, and COX-2 expres-
sion in HBV WT-transfected/Phyllanthus extract-treated
HepG2 cells may induce the expression of IFN-inducible
genes and/or different inflammatory mediators, which
then inhibit HBV replication.
Taken together, the data presented herein suggest three
possible mechanisms underlying the anti-HBV activity of
Phyllanthus extract: (i) Phyllanthus extract directly in-
hibits hepadnaviral P protein [38]; (ii) because Phyllanthus
extract alone did not induce a signaling cascade in HepG2
cells (Fig. 5), Phyllanthus extract works in conjunction
with HBV replication and/or HBV protein and RNA ex-
pression to inhibit HBV replication by inducing IFN-β,
COX-2, and IL-6 expression; (iii) since intracellular HBV
RNAs, proteins, and core particles were unaffected by
Phyllanthus extract (Fig. 2c-d), these molecules might
stimulate the innate immune response to further inhibit
HBV replication. These hypotheses are not mutually ex-
clusive and they may work in concert with each other.
Conclusion
The results presented herein demonstrate that Phyllanthus
extract effectively inhibits the replication of LMV-resistant
HBV. Phyllanthus extract appears to inhibit HBV replica-
tion by inducing the expression of IFN-β, COX-2, and IL-6,
which in turn activate the innate immune response. Thus,
Phyllanthus extract may be a therapeutic agent useful for
the management of LMV-resistant CHB patients; However,
the detailed antiviral mechanisms and in vivo efficacy re-
quire further investigation.
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